Evaluation of the protective effect of a new beta-agonist, KWD 2131, on allergen-induced bronchospasm.
The selective anti-allergic effect of a new beta-agonist, KWD 2131, in inhibiting allergen-provoked asthma was compared with that of placebo in a double-blind crossover study. Non-bronchodilating doses were given by inhalation to 12 asymptomatic patients with extrinsic asthma. KWD 2131 showed a marginal anti-allergic effect. A significantly better effect than that with placebo was obtained at only one time of measurement after challenge (P < 0.05). The reproducibility of the allergen challenge was also evaluated. The mean maximum decrease in FEV1 during three different allergen-challenge procedures was 37, 31, and 38%, respectively. The difference was not statistically significant.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000485:Allergens; D001249:Asthma / Q000188:drug therapy; D001985:Bronchial Provocation Tests; D001986:Bronchial Spasm / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D010919:Placebos; D013726:Terbutaline / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D000485:Allergens; D010919:Placebos; C025075:KWD 2131; D013726:Terbutaline